EU-FDA MRA: Soon all States on board
Recommendation
27/28 May 2026
Batch Manufacturing Documents: from Preparation to Operational Excellence
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The Mutual Recognition Agreement (MRA) with the USA was supplemented by two further countries: Poland and Slovenia. Now 22 countries are already recognised. Among other countries, Germany is still missing . On a dedicated webpage of the EMA there is an excellent overview. By 15 July 2019, however, all authorities and countries should have been inspected and approved.
If the agreement is fully in force (and only then!), the additional full testing of a drug imported from the USA will no longer be necessary. This also applies to countries that have already been recognised.
No more inspections?
In exceptional cases, the FDA will continue to travel to the EU for inspections, among other things within the framework of approval procedures (so-called pre-approval inspections). This also became clear at an ECA conference in November 2018, where participants from Spain, Austria and Denmark reported on announced inspections for the year 2019.
Related GMP News
22.04.2026No Validation, No Controls, and No Suitable Rooms and Equipment - Extensive Warning Letter
25.03.2026FDA Warning Letter highlights once again: Weaknesses in the CAPA Process remain a key GMP Issue
18.03.2026FDA Issues Draft Guidance on Responding to Form 483 Observations
28.01.2026What is the Procedure for GMP Inspections (EU GMP inspections and FDA Inspections)?
21.01.2026FDA Warning Letter highlights critical Failures in Supplier and Quality Oversight
19.01.2026GMP Auditor Association Developments September through December 2025